Product Description
Astellas Pharma was developing asp-6282, an oral drug, for the treatment of underactive bladder (Sourced from: https://www.astellas.com/system/files/news/2018-03/20150527_Eg.pdf)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02420782 |
First-in-human | P1 |
Completed |
Healthy Volunteers |
2016-05-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|